FINWIRES · TerminalLIVE
FINWIRES

$ALKS

12 stories mentioning ALKSUpdated 1d ago

Every FINWIRES story that references ALKS, newest first.

Wire

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

Alkermes' (ALKS) base business supported the company's Q2 beat, while its orexin pipeline serves as a potential catalyst for future revenue growth, RBC Capital Markets said in a Tuesday note.The company reported a breakeven in Q2, compared with earnings of $0.52 per share a year earlier, and revenue of $496 million, up from $390.7 million. For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion.Alkermes' core business drove the quarter's revenue beat, with recent highlights like less generic threat for Vivitrol and expanded access for Lybalvi, RBC said. The quarter also said one-time benefits from patient mix favorability, Lumryz inventory and Consta manufacturing, the brokerage added.Looking forward, investor focus is shifting to the company's orexin pipeline expansion into other indications, which could help pave the way for Alkermes's revenue to exceed $5 billion, RBC noted.RBC has an outperform rating and $56 price target on Alkermes.Price: $48.40, Change: $-2.11, Percent Change: -4.17%

$ALKS
Insider Trading

Alkermes Insider Sold Shares Worth $463,621, According to a Recent SEC Filing

Craig C. Hopkinson, Executive Vice President of Research and Development and Chief Medical Officer, on July 01, 2026, sold 9,000 shares in Alkermes (ALKS) for $463,621. Following the Form 4 filing with the SEC, Hopkinson has control over a total of 73,389 ordinary shares of the company, with 73,389 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1520262/000152026226000103/xslF345X05/form4.xml

$ALKS
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) gaining 0.2%.The iShares Biotechnology ETF (IBB) rose 0.9%.In corporate news, Zymeworks (ZYME) has agreed to buy Theravance Biopharma (TBPH) for $17 per share in a roughly $929 million deal, the companies said in separate statements. Zymeworks shares were down 0.6%, and Theravance fell 3.2%.Abbott Laboratories (ABT) shares were down 1.3%. The Wall Street Journal reported Sunday the company will not face criminal charges after the US Department of Justice closed a years-long investigation into its baby formula operations.QuidelOrtho (QDEL) shares surged 34%. The company is weighing the sale of its point-of-care testing business behind rapid COVID-19 antigen tests for about $1.5 billion, the Financial Times reported Saturday.Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a note Monday. BofA downgraded Alkermes to underperform from neutral with a price target of $38. Shares were down 4.7%.

$ABT$ALKS$QDEL$TBPH$ZYME
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.The iShares Biotechnology ETF (IBB) rose 0.9%.In corporate news, Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday. BofA downgraded Alkermes to underperform from neutral with a price target of $38. Alkermes shares were down 4.6%.

$ALKS
Wire

Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says

Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin updates risk eroding newly ascribed orexin-related value, BofA Securities said in a research note Monday.ALKS largely trades on data points informing the commercial opportunity for its phase 2 and phase 3 pipeline asset orexin in hypersomnolent disorders, the brokerage said.The firm said possible negative catalysts include Alkermes' phase 2 Vibrance-3 data in idiopathic hypersomnia, reading out late 2026 or early 2027.BofA sees idiopathic hypersomnia as a risky segment in the broader hypersomnia market, as competition from Takeda Pharmaceutical's (TAK) phase 2 data for TAK-360 in narcolepsy type 2 and idiopathic hypersomnia could reinforce the narrative that the market is crowded. Key opinion leaders have also flagged lower unmet need for another wake promoter, and BofA sees profit and loss risk as well, according to the note.BofA downgraded Alkermes to underperform from neutral with a price target of $38.Price: $52.85, Change: $-2.23, Percent Change: -4.05%

$ALKS
Wire

Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says

Alkermes' (ALKS) work on developing applications for orexin agonists outside of sleep indications can reposition the firm as a leader in the space, RBC Capital Markets said in a Monday note.As orexin in sleep become ever more crowded, the report said interest in other applications build. RBC analysts project a 50/50 split across the base business and future pipeline."While there may be potential in at least 5 major disorders, we see the strongest support for ADHD and addiction," they said.Alkermes is studying orexin applications for ADHD and fatigue, with initial ADHD data expected in Q4, according to the note."We think near-term data catalysts for these programs can help investors reframe ALKS as a leader in the space," the note said.RBC raised its price target to $56 from $45 while maintaining its outperform rating.Price: $43.13, Change: $+0.68, Percent Change: +1.61%

$ALKS
Insider Trading

Alkermes Insider Sold Shares Worth $687,007, According to a Recent SEC Filing

Samuel Joseph Parisi, Vice President, Finance (Interim Principal Accounting Officer), on May 29, 2026, sold 16,217 shares in Alkermes (ALKS) for $687,007. Following the Form 4 filing with the SEC, Parisi Samuel Joseph has control over a total of 7,717 ordinary shares of the company, with 7,717 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1520262/000152026226000095/xslF345X05/form4.xml

$ALKS
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each rising about 2%.The iShares Biotechnology ETF (IBB) increased 1.2%.In sector news, President Donald Trump said Tuesday that US Food and Drug Administration Commissioner Marty Makary is resigning, Bloomberg reported.In corporate news, West Pharmaceutical Services (WST) shares were down 3% after the company said in a regulatory filing its global operations were disrupted by a cyberattack.Alkermes (ALKS) shares jumped past 7% after the firm said Tuesday a late-stage trial of Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and secondary targets.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC said in a note. RBC kept its outperform rating and raised its price target to $45 from $39. Shares eased 0.2%.Dr. Reddy's Laboratories (RDY) plans to launch a generic version of Novo Nordisk's (NVO) Ozempic this month in Canada, Bloomberg reported Tuesday, citing Chief Executive Erez Israeli. Dr. Reddy's shares fell 5.3%, and Novo rose 1.1%.

$ALKS$NVO$RDY$SNDA$WST
Sectors

Sector Update: Healthcare Stocks Gain in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.The iShares Biotechnology ETF (IBB) increased 1.4%.In corporate news, Alkermes (ALKS) shares jumped past 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.Sonida Senior Living's (SNDA) recent stock decline was unwarranted given the broad-based strength in its Q1 results, RBC Capital Markets said in a note. RBC reiterated its outperform rating on the stock and raised its price target to $45 per share from $39. Sonida shares added 1.5%.Agios Pharmaceuticals (AGIO) shares rose 1% after it said Tuesday it has submitted a supplemental New Drug Application to the US Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.

$AGIO$ALKS$SNDA
Sectors

Sector Update: Healthcare

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 2.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) climbing 2.2%.The iShares Biotechnology ETF (IBB) increased 1.4%.In corporate news, Alkermes (ALKS) shares jumped 5% after it said Tuesday a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints.

$ALKS
Sectors

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% higher.Sionna Therapeutics (SION) shares were down more than 5% after the company reported a wider-than-expected Q1 net loss.Alkermes (ALKS) said a late-stage trial evaluating its investigational Lumryz oral suspension in adults with idiopathic hypersomnia, a rare condition in which patients require excessive sleep, met all primary and key secondary endpoints. Alkermes stock was up more than 2% pre-bell.BridgeBio Pharma (BBIO) shares were up more than 1% after the company said it has submitted a new drug application to the US Food and Drug Administration for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition affecting calcium levels.

$ALKS$BBIO$IBB$SION$XLV
Wire

Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says

Alkermes' (ALKS) better-than-expected Q1 revenue highlights the "underappreciated nature" of the company's core business, analysts at RBC Capital Markets said in a Tuesday note.Management remains confident in the company's competitive position and multiple catalysts can serve as value inflection points, including phase 2 and phase 3 three idiopathic hypersomnia data and early stage ADHD data, the RBC analysts said.Q1 royalty revenue came in better than expected, helped by a strong quarter for Vumerity. RBC now expects $1.81 billion in 2026 revenue and said if the strength continues in Q2, the company could point investors to the higher end of its guidance range, according to the note.RBC said it is looking forward to alixorexton data in idiopathic hypersomnia in H2, which could add another $1 billion in 2035 sales, for a total opportunity of more than $3 billion.While revenue is strong, the company is maintaining its product-by-product and total revenue guidance of $1.73 billion to $1.84 billion, the brokerage added.RBC maintained an outperform rating on Alkermes with a price target of $44.Price: $35.55, Change: $-0.70, Percent Change: -1.93%

$ALKS

Track with the FINWIRES app suite

FolioX
FolioX
Track ALKS in your portfolio
WheelAI
WheelAI
Analyze ALKS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ALKS